期刊文献+

人CD34单链抗体基因的构建及序列测定 被引量:3

Construction and sequence analysis of anti CD34 single chain antibody gene
原文传递
导出
摘要 目的:获得抗人CD34单链抗体基因。方法:选用一株分泌抗CD34抗原单克隆抗体的杂交瘤细胞株,提取总RNA,经RT-PCR扩增出此抗体的重链可变区和轻链可变区基因,与Kabat抗体库比较得到其框架区和互补决定区的氨基酸序列;重新合成两对引物去掉保留的分泌信号前导序列并加入适当的限制性内切酶酶切位点,再经PCR得到所需要的重链可变区和轻链可变区基因,经一弹性连接肽连接构建成抗人CD34的单链抗体(sFv)基因。结果:DNA序列分析结果表明,获得的单链抗体基因的轻链可变区属于鼠κ轻链第Ⅴ亚族,重链可变区属于鼠重链第Ⅰ(B)亚族。结论:构建的抗人CD34单链抗体基因全长为813个碱基,编码蛋白的相对分子质量约为30000。 Objective: Cloning of anti CD34 single chain antibody gene. Methods: A hybridoma which can secrete anti CD34 monoclonal antibody was used in the construction of single chain antibody (sFv) gene. The cells were used for preparation of total cellular RNA and the cDNAs of the variable heavy chain (V H) and light chain (V L) regions were synthesized by RT PCR. Then framework regions (FR) and complementary determining regions (CDR) of the antibody were determined by using the Kabat antibody sequence database and new PCR primers containing appropriate restriction enzyme sites for further cloning were used to reamplify each of the V L and V H fragments, with deletion of the remaining secretory leader sequences. The DNAs of light and heavy chain were joined together via a flexible linker to obtain anti CD34 sFv gene. Results: The sequence analysis demonstrated that the V L and V H belong to kappa light chain subgroup V and heavy chain subgroup Ⅰ(B) of mouse variable region respectively. Conclusion: The complete sFv construct, including linker sequence, is 813bp and the molecular weight of encoded protein is approximately 30 kDa.
出处 《军事医学科学院院刊》 CSCD 北大核心 1999年第1期1-4,共4页 Bulletin of the Academy of Military Medical Sciences
关键词 CD34 单链抗体 克隆 序列分析 聚合酶链反应 CD34 sFv clone sequence analysis polymerase chain reaction
  • 相关文献

参考文献3

  • 1Laevy Mintz P,J Virol,1996年,70卷,8821页
  • 2Duan L X,Proc Nat Acad Sci USA,1994年,91卷,11期,50页
  • 3Kabat E A,Sequence of protein of immunlolgical interest,1991年,1281页

同被引文献16

引证文献3

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部